Clinical trials: Early Parkinson Disease (Early PD)
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Parkinson's Disease
Study of Urate Elevation in Parkinson's Disease, Phase 3
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early…
- Trial name
- SURE-PD3 (NCT02642393)
- Testing
- Inosine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- Michael Alan Schwarzschild
Parkinson's Disease
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
- Trial name
- NCT00203060
- Testing
- Rasagiline Mesylate
- Volunteers
- 404 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinsons Disease (PD)
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1.
- Trial name
- PDGSH (NCT07064005)
- Testing
- Gamma- glutamylcysteine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pravat Mandal
Parkinson's Disease
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)
The purpose of this study is to investigate genetic and environmental risk factors that increase susceptibility to the development of early-onset Parkinson's disease (developed at or before age 50).
- Trial name
- NCT00104585
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Columbia University
Parkinson Disease, Parkinson
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich…
- Conditions
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
- Trial name
- NEULARK (NCT06680830)
- Testing
- NEU-411
- Where
- 72 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Neuron23 Inc.
Parkinson Disease (PD), Cognition
Short Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease.
The goal of this clinical trial is to learn if the Ronnie Gardiner Method (RGM) works to improve cognitive functions in adults with Parkinson's disease (early to mid-stage).
- Conditions
- Parkinson Disease (PD), Cognition, Quality of Life, Functional Mobility
- Trial name
- NCT07863219
- Testing
- Ronnie Gardiner Method
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Ghent
Parkinson Disease (PD), Idiopathic Parkinson's Disease
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.
- Trial name
- NCT07840027
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Tridem Bioscience FlexCo
Idiopathic Parkinson's Disease
Walking Capacity in Parkinson's Disease (PD-Walk)
The major aim of this study is to determine the efficacy of a home-based treadmill walking program in improving walking capacity and quality of life in people with early mid-stage Parkinson's disease(PD).
- Trial name
- NCT00261781
- Testing
- Treadmill training
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Natalie Allen
Parkinson Disease
Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease
Pre-Active PD is a randomized controlled feasibility study to evaluate the implementation of a telehealth-delivered physical activity behavior change intervention for people with early-mid stage Parkinson's disease.
- Trial name
- NCT05308238
- Testing
- Occupational therapy intervention group, Disease management education group
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- San Jose State University
PARKINSON DISEASE (Disorder)
Early COMT Inhibition in PD
This prospective, randomized, assessor-blinded, parallel-group clinical trial aims to compare the effectiveness of early add-on opicapone versus levodopa dose escalation in patients with Parkinson's disease experiencing emerging…
- Trial name
- OPITECH (NCT07917546)
- Testing
- Opicapone 50 mg, L-DOPA/DDCI
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Neuromed IRCCS
Early Stage Non-small Cell Lung Cancer
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT04530227
- Testing
- Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Parkinson's Disease
MIRT and Rotigotine in the Early Stage of PD
To test whether a multidisciplinary intensive rehabilitation treatment (MIRT) slowed down the progression of the disease in Parkinson's disease (PD) "de novo" patients, all treated with Rotigotine, in a randomized controlled…
- Trial name
- MIRT-RT (NCT02100176)
- Testing
- Multidisciplinary intensive rehabilitation treatment, Rotigotine
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
REM Sleep Behavior Disorder, Parkinson's Disease
Evolution of RBD in PD
About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid…
- Trial name
- NCT03047408
- Testing
- Video polysomnography
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Parkinson Disease
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
The objectives of this trial conducted in early Parkinson's disease (PD) patients are: To assess if patients with early Parkinson's disease (PD) can be successfully switched (overnight switching) from Pramipexole (PPX) Immediate…
- Trial name
- NCT00558025
- Testing
- Pramipexole Extended Release, Pramipexole Immediate Release
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
In Parkinson's disease (PD), alpha-synuclein accumulation in cutaneous autonomic pilomotor and sudomotor nerve fibers has been linked to autonomic nervous system disturbances even in the early stages of the disease.
- Trial name
- CAPTURE-PD (NCT03043768)
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GWT-TUD GmbH
Parkinson Disease (PD)
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
This observational, multicenter, case-control study aims to evaluate the efficacy and safety of Entacapone combined with Madopar (levodopa/benserazide) in the treatment of early-stage Parkinson's disease (PD) among Chinese…
- Trial name
- NCT06928519
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Yousheng Xiao
Parkinson Disease
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind…
- Trial name
- NCT00601523
- Testing
- Pramipexole
- Where
- 119 sites in United States, Austria and 13 more
- Volunteers
- 511 people
- Sponsor
- Boehringer Ingelheim